JP2020501162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501162A5 JP2020501162A5 JP2019532928A JP2019532928A JP2020501162A5 JP 2020501162 A5 JP2020501162 A5 JP 2020501162A5 JP 2019532928 A JP2019532928 A JP 2019532928A JP 2019532928 A JP2019532928 A JP 2019532928A JP 2020501162 A5 JP2020501162 A5 JP 2020501162A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv16
- antibody
- antigen
- capsid
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 claims description 28
- 210000000234 capsid Anatomy 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 19
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000011394 anticancer treatment Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000013610 patient sample Substances 0.000 claims description 5
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 3
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000005653 Brownian motion process Effects 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022200001A JP2023029377A (ja) | 2016-12-13 | 2022-12-15 | Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102016124171.7A DE102016124171A1 (de) | 2016-12-13 | 2016-12-13 | Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen |
| DE102016124171.7 | 2016-12-13 | ||
| PCT/EP2017/082506 WO2018108957A1 (en) | 2016-12-13 | 2017-12-13 | Serologic test for therapy control of hpv16 positive carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022200001A Division JP2023029377A (ja) | 2016-12-13 | 2022-12-15 | Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501162A JP2020501162A (ja) | 2020-01-16 |
| JP2020501162A5 true JP2020501162A5 (https=) | 2021-02-04 |
| JP7329244B2 JP7329244B2 (ja) | 2023-08-18 |
Family
ID=61027644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532928A Active JP7329244B2 (ja) | 2016-12-13 | 2017-12-13 | Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 |
| JP2022200001A Pending JP2023029377A (ja) | 2016-12-13 | 2022-12-15 | Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022200001A Pending JP2023029377A (ja) | 2016-12-13 | 2022-12-15 | Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10852303B2 (https=) |
| EP (1) | EP3384292B1 (https=) |
| JP (2) | JP7329244B2 (https=) |
| KR (1) | KR102433541B1 (https=) |
| CN (1) | CN110073219B (https=) |
| BR (1) | BR112019011681A2 (https=) |
| CA (1) | CA3045729A1 (https=) |
| CY (1) | CY1124297T1 (https=) |
| DE (1) | DE102016124171A1 (https=) |
| DK (1) | DK3384292T3 (https=) |
| ES (1) | ES2880489T3 (https=) |
| HR (1) | HRP20211080T1 (https=) |
| HU (1) | HUE054969T2 (https=) |
| LT (1) | LT3384292T (https=) |
| PL (1) | PL3384292T3 (https=) |
| PT (1) | PT3384292T (https=) |
| RS (1) | RS62135B1 (https=) |
| RU (1) | RU2757629C2 (https=) |
| SI (1) | SI3384292T1 (https=) |
| SM (1) | SMT202100421T1 (https=) |
| WO (1) | WO2018108957A1 (https=) |
| ZA (1) | ZA201804516B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102022127779A1 (de) | 2022-10-20 | 2024-04-25 | Ralf Hilfrich | Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8062642B1 (en) * | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
| US20020193565A1 (en) * | 1998-03-27 | 2002-12-19 | Stanley Margaret Anne | Antigen preparation and use |
| US7067258B2 (en) * | 2002-04-30 | 2006-06-27 | Merck & Co., Inc. | Human papillomavirus multiplexed assay |
| CN101245099A (zh) * | 2007-02-14 | 2008-08-20 | 马润林 | 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用 |
| WO2010118424A2 (en) * | 2009-04-10 | 2010-10-14 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| DE102010061028A1 (de) * | 2010-12-03 | 2012-06-06 | Ralf Hilfrich | Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests |
| DE102011053741A1 (de) * | 2011-09-19 | 2013-03-21 | Ralf Hilfrich | Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen |
-
2016
- 2016-12-13 DE DE102016124171.7A patent/DE102016124171A1/de not_active Withdrawn
-
2017
- 2017-12-13 PT PT178356028T patent/PT3384292T/pt unknown
- 2017-12-13 DK DK17835602.8T patent/DK3384292T3/da active
- 2017-12-13 US US16/090,159 patent/US10852303B2/en active Active
- 2017-12-13 SM SM20210421T patent/SMT202100421T1/it unknown
- 2017-12-13 BR BR112019011681-8A patent/BR112019011681A2/pt not_active IP Right Cessation
- 2017-12-13 PL PL17835602T patent/PL3384292T3/pl unknown
- 2017-12-13 SI SI201730846T patent/SI3384292T1/sl unknown
- 2017-12-13 WO PCT/EP2017/082506 patent/WO2018108957A1/en not_active Ceased
- 2017-12-13 EP EP17835602.8A patent/EP3384292B1/en active Active
- 2017-12-13 KR KR1020197020463A patent/KR102433541B1/ko active Active
- 2017-12-13 CA CA3045729A patent/CA3045729A1/en active Pending
- 2017-12-13 HR HRP20211080TT patent/HRP20211080T1/hr unknown
- 2017-12-13 ES ES17835602T patent/ES2880489T3/es active Active
- 2017-12-13 JP JP2019532928A patent/JP7329244B2/ja active Active
- 2017-12-13 CN CN201780077269.1A patent/CN110073219B/zh not_active Expired - Fee Related
- 2017-12-13 RU RU2019121882A patent/RU2757629C2/ru active
- 2017-12-13 HU HUE17835602A patent/HUE054969T2/hu unknown
- 2017-12-13 RS RS20210859A patent/RS62135B1/sr unknown
- 2017-12-13 LT LTEP17835602.8T patent/LT3384292T/lt unknown
-
2018
- 2018-07-06 ZA ZA2018/04516A patent/ZA201804516B/en unknown
-
2020
- 2020-09-09 US US17/015,955 patent/US11506667B2/en active Active
-
2021
- 2021-07-06 CY CY20211100609T patent/CY1124297T1/el unknown
-
2022
- 2022-12-15 JP JP2022200001A patent/JP2023029377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Canziani et al. | Kinetic screening of antibodies from crude hybridoma samples using Biacore | |
| JP2015533788A5 (https=) | ||
| JP2020522261A5 (https=) | ||
| CN112062851B (zh) | 靶向bcma嵌合抗原受体的抗体及其应用 | |
| AU2011281700B2 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
| AU2015265870A1 (en) | PD-L1 antibodies and uses thereof | |
| JP2020536507A5 (https=) | ||
| JP2012515226A5 (https=) | ||
| JP2013174616A (ja) | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 | |
| Masuda et al. | Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine | |
| JP2005504513A5 (https=) | ||
| EP3649152A1 (en) | Ror1 antibodies | |
| Liu et al. | Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer | |
| AU2011281706A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| RU2014106658A (ru) | Новое антитело к cxcr4 и его применение для выявления и диагностики рака | |
| Sakane et al. | A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma | |
| RU2013142334A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а | |
| RS64388B1 (sr) | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| Thierry et al. | Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells | |
| JP2020501162A5 (https=) | ||
| JP2021528411A5 (https=) | ||
| JP2020515286A5 (https=) | ||
| Lee et al. | A high-sensitivity cfDNA capture enables to detect the BRAF V600E mutation in papillary thyroid carcinoma | |
| RU2019121882A (ru) | Серологический тест для терапевтического контроля впч-16-положительной карциномы |